利用代谢组学预测重型创伤性脑损伤3个月和12个月时的GOSE结局
该研究为加拿大CanTBI多中心前瞻性研究,纳入59例成人重型创伤性脑损伤(GCS≤8),于伤后第1天和第4天采血,用靶向DI/LC-MS/MS和非靶向1H-NMR进行血清代谢组学分析,并在伤后3个月和12个月收集GOSE(二分为有利结局GOSE 5-8与不利结局GOSE 1-4)。结果显示,第1天和第4天代谢谱预测3个月和12个月GOSE结局及3个月死亡率高度准确(AUC>0.99),第4天代谢谱比第1天更具预测性(Q2>0.55)。不利结局与第1天至第4天代谢物较大变化相关,溶血磷脂酰胆碱、酰基肉碱、能量相关代谢物(葡萄糖、乳酸)、芳香族氨基酸和谷氨酸升高与不良结局和死亡相关。作者认为这些发现强烈支持血清代谢组学在sTBI早期预后判断中的应用,且优于临床数据,但需在更大队列中验证。
要点
- 成人sTBI(GCS≤8)伤后第1天和第4天血清代谢谱预测3个月和12个月GOSE结局及3个月死亡率高度准确(AUC>0.99)。
- 第4天代谢谱比第1天更具预测性(Q2>0.55 vs Q2>0.4-0.5),可能反映继发性脑损伤对sTBI结局的贡献更大。
- 不利结局(GOSE 1-4)患者从第1天到第4天的代谢物变化比有利结局(GOSE 5-8)患者更大。
- 溶血磷脂酰胆碱、酰基肉碱、能量相关代谢物(葡萄糖、乳酸)、芳香族氨基酸和谷氨酸升高与不良结局和死亡相关。
- 作者认为血清代谢组学在sTBI早期预后判断中优于临床数据,但需在更大的成人sTBI队列中验证后才能用于临床实践。
适用人群与场景
- 加拿大CanTBI多中心研究前瞻性纳入的59例成人重型创伤性脑损伤患者(GCS≤8)。
诊断标准与关键阈值
- 重型创伤性脑损伤定义为格拉斯哥昏迷量表(GCS)≤8。
- 结局用格拉斯哥结局扩展量表(GOSE)评估,二分为有利结局(GOSE 5-8)和不利结局(GOSE 1-4)。
研究设计与关键结果
- 研究类型为多中心前瞻性研究,纳入59例成人sTBI(GCS≤8),于伤后第1天和第4天采血,用靶向DI/LC-MS/MS和非靶向1H-NMR进行血清代谢组学分析,在伤后3个月和12个月收集GOSE。
- 伤后第1天和第4天血清代谢谱预测3个月和12个月GOSE结局及3个月死亡率高度准确(AUC>0.99),且高度预测(Q2>0.4-0.5)。
- 第4天代谢谱比第1天更具预测性(Q2>0.55 vs Q2>0.4-0.5)。
- 不利结局患者从第1天到第4天的代谢物变化比有利结局患者更大。
- 溶血磷脂酰胆碱、酰基肉碱、能量相关代谢物(葡萄糖、乳酸)、芳香族氨基酸和谷氨酸升高与不良结局和死亡相关。
- 第4天神经生物标志物如N-乙酰天冬氨酸(NAA)和酪氨酸浓度升高、酮体浓度降低、尿素循环代谢物降低,可能是预测结局的潜在代谢物。
证据类型、等级与局限
- 证据类型:多中心前瞻性队列研究。
- 局限:作者指出研究结果需在更大的成人sTBI队列中验证后才能用于临床实践。
对床旁实践的改变
- 作者认为血清代谢组学在成人sTBI伤后早期预后判断中优于临床数据,但研究结果需在更大的成人sTBI队列中验证后才能用于临床实践。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Prognostication is very important to clinicians and families during the early management of severe traumatic brain injury (sTBI), however, there are no gold standard biomarkers to determine prognosis in sTBI. As has been demonstrated in several diseases, early measurement of serum metabolomic profiles can be used as sensitive and specific biomarkers to predict outcomes.
METHODS: We prospectively enrolled 59 adults with sTBI (Glasgow coma scale, GCS ≤ 8) in a multicenter Canadian TBI (CanTBI) study. Serum samples were drawn for metabolomic profiling on the 1st and 4th days following injury. The Glasgow outcome scale extended (GOSE) was collected at 3- and 12-months post-injury. Targeted direct infusion liquid chromatography-tandem mass spectrometry (DI/LC-MS/MS) and untargeted proton nuclear magnetic resonance spectroscopy (1H-NMR) were used to profile serum metabolites. Multivariate analysis was used to determine the association between serum metabolomics and GOSE, dichotomized into favorable (GOSE 5-8) and unfavorable (GOSE 1-4), outcomes.
RESULTS: Serum metabolic profiles on days 1 and 4 post-injury were highly predictive (Q2 > 0.4-0.5) and highly accurate (AUC > 0.99) to predict GOSE outcome at 3- and 12-months post-injury and mortality at 3 months. The metabolic profiles on day 4 were more predictive (Q2 > 0.55) than those measured on day 1 post-injury. Unfavorable outcomes were associated with considerable metabolite changes from day 1 to day 4 compared to favorable outcomes. Increased lysophosphatidylcholines, acylcarnitines, energy-related metabolites (glucose, lactate), aromatic amino acids, and glutamate were associated with poor outcomes and mortality.
DISCUSSION: Metabolomic profiles were strongly associated with the prognosis of GOSE outcome at 3 and 12 months and mortality following sTBI in adults. The metabolic phenotypes on day 4 post-injury were more predictive and significant for predicting the sTBI outcome compared to the day 1 sample. This may reflect the larger contribution of secondary brain injury (day 4) to sTBI outcome. Patients with unfavorable outcomes demonstrated more metabolite changes from day 1 to day 4 post-injury. These findings highlighted increased concentration of neurobiomarkers such as N-acetylaspartate (NAA) and tyrosine, decreased concentrations of ketone bodies, and decreased urea cycle metabolites on day 4 presenting potential metabolites to predict the outcome. The current findings strongly support the use of serum metabolomics, that are shown to be better than clinical data, in determining prognosis in adults with sTBI in the early days post-injury. Our findings, however, require validation in a larger cohort of adults with sTBI to be used for clinical practice.
参考来源
- Banoei MM, Lee CH, Hutchison J, et al. Using metabolomics to predict severe traumatic brain injury outcome (GOSE) at 3 and 12 months. Crit Care. 2023. PMID: 37481590. doi:10.1186/s13054-023-04573-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。